. 2021 Nov 26;6(1):bvab179. doi: 10.1210/jendso/bvab179

Table 5.

Longitudinal changes in therapeutic and biochemical parameters during the trial

Parameter	Placebo (n = 18)		Ergocalciferol (n = 18)		Placebo (n = 18)		Ergocalciferol (n = 18)		P
	Mean	SD	Mean	SD	LSE Mean	SE	LSE mean	SE	Difference in overall mean	Overall trend	Difference in trend	Difference at specific time (adjusted for multiple comparisons)
TDDI, units/kg/d									.046	.001	.097
Baseline	0.48	0.23	0.51	0.23	0.48	0.05	0.55	0.06				.41
Mo 3	0.46	0.18	0.62	0.36	0.43	0.05	0.62	0.08				.049
Mo 6	0.49	0.27	0.62	0.30	0.48	0.06	0.67	0.08				.06
Mo 9	0.62	0.28	0.69	0.26	0.63	0.07	0.73	0.07				.31
Mo 12	0.67	0.30	0.65	0.24	0.67	0.07	0.72	0.07				.65
FBG, mg/dL									.13	.03	.10
Baseline	111	36	126	25	115	9	126	6				.31
Mo 3	131	53	157	61	130	12	157	15				.17
Mo 6	146	72	146	54	146	17	147	14				.97
Mo 9	140	61	141	43	137	16	143	12				.75
Mo 12	158	61	145	49	158	15	145	14				.52
Fasting C-peptide, ng/mL									.54	.01	.72
Baseline	0.68	0.40	0.80	0.82	0.71	0.10	0.80	0.19				.67
Mo 3	0.65	0.38	0.59	0.40	0.69	0.09	0.71	0.12				.90
Mo 6	0.71	0.55	0.46	0.29	0.71	0.13	0.51	0.08				.19
Mo 9	0.44	0.24	0.42	0.24	0.49	0.07	0.46	0.06				.80
Mo 12	0.50	0.47	0.35	0.21	0.50	0.11	0.37	0.06				.29
Stimulated C-peptide, ng/mL									.08	< .001	.31
Baseline	2.22	1.31	1.78	1.18	2.27	0.31	1.78	0.28				.24
Mo 3	1.74	0.94	1.28	0.78	1.76	0.21	1.56	0.25				.55
Mo 6	1.51	1.08	1.17	0.92	1.53	0.25	1.40	0.26				.73
Mo 9	1.35	1.34	1.05	0.84	1.36	0.31	1.25	0.24				.79
Mo 12	1.14	1.27	0.82	0.77	1.15	0.29	1.05	0.22				.80
HbA_1c, %									.09	< .001	.04
Baseline	7.47	1.69	7.62	1.35	7.47	0.39	7.62	0.32				.76
Mo 3	6.67	1.23	7.20	1.54	6.67	0.28	7.25	0.37				.21
Mo 6	7.12	1.51	7.26	1.18	7.15	0.34	7.28	0.27				.77
Mo 9	7.59	1.37	7.50	1.42	7.61	0.32	7.48	0.35				.77
Mo 12	8.01	1.70	7.64	2.14	8.03	0.41	7.65	0.57				.59
IDAA_1c									.03	< .001	.02
Baseline	9.4	2.4	9.7	1.8	9.4	0.6	9.9	0.4				.51
Mo 3	8.5	1.8	9.7	2.3	8.4	0.4	9.7	0.6				.05
Mo 6	9.0	2.4	9.8	1.9	9.0	0.5	10.0	0.5				.17
Mo 9	10.1	2.2	10.2	2.1	10.1	0.5	10.4	0.5				.62
Mo 12	10.7	2.5	10.3	2.3	10.7	0.6	10.6	0.6				.89

P values were obtained from repeated-measures trend analysis using generalized linear model with dependent variable equal to clinical parameter, and independent variables equal to group, time, and their interactions. Generalized estimating equation was used for repeated measures.

Abbreviations: FBG, fasting blood glucose; HbA_1c, glycated hemoglobin A_1c; IDAA_1c, insulin dose–adjusted A_1c; LSE, least square estimate; TDDI, total daily dose of insulin.